KEY DETAILS
The World Health Organization now recommends diet, exercise and counseling ahead of weight-loss drugs for younger children with obesity.
Eli Lilly secured FDA orphan drug status for olomorasib, a pancreatic cancer treatment, signaling a push beyond its GLP-1 lineup.
Nutritionists caution that 'GLP-1-friendly' labels on food packaging may not be as reliable a guide as shoppers assume.
A new study found isometric exercises like squats and planks work best three times weekly for lowering blood pressure in the short term.
Teen prescribing of GLP-1 drugs rose sharply from 2017 to 2025, yet most bariatric surgery-eligible teens still did not receive one.
The World Health Organization issued its first global guidelines on childhood obesity this week, and the recommendation is clear: diet, exercise and counseling should come before weight-loss drugs for younger children. That decision sets the tone for a day that also touched teenagers already on GLP-1 prescriptions, food labels that may not mean what they claim, and a cancer drug that shows Eli Lilly's ambitions reaching beyond its weight-loss franchise. For parents, shoppers and patients alike, today's developments ask the same question in different ways: what can you trust?
The guidelines, released Wednesday, mark the WHO's first attempt to set a global standard for treating obesity in younger children, and the message is straightforward. Start with changes to food and activity, and lean on counseling, before reaching for a prescription. The organization did not rule out medication altogether, but it placed weight-loss drugs further down the list of options for this age group, reflecting limited long-term safety data in children. For pediatricians and families, that ordering changes the conversation, shifting early appointments toward habits and support rather than a prescription pad.
That caution around GLP-1 drugs for children did not slow things down at Eli Lilly, whose attention this week turned toward a different kind of treatment entirely. The company secured FDA orphan drug status for olomorasib, an experimental pancreatic cancer treatment, a designation reserved for drugs aimed at rare diseases. The move signals that Lilly is building a pipeline well beyond the GLP-1 drugs that made it a household name, and it suggests the company sees its future resting on more than one category of medicine.
Lilly's push into cancer treatment says something about where the company expects growth beyond weight-loss drugs, but for the millions of people already using GLP-1 medications, a more immediate question sits in the grocery aisle. Nutritionists are cautioning that food packaging labeled 'GLP-1-friendly' may not be as reliable a guide as shoppers assume. The label can suggest a product supports appetite control or fits a GLP-1 regimen without that claim being backed by the kind of evidence a patient might expect. Anyone relying on these labels to plan meals may want to read the ingredient list as closely as the marketing on the front of the box.
Food labels are one place people look for an edge in managing their health, and a new study points to another, built on a different kind of discipline than diet alone. Researchers found that isometric exercises, including squats and plank holds, worked best for lowering blood pressure in the short term when done three times a week. The randomized study, published in BMJ Open Sport & Exercise Medicine, adds to a growing body of evidence that structured movement can meaningfully affect blood pressure without medication. For readers looking for lifestyle tools that complement or substitute for drug therapy, this is a concrete and low-cost option to raise with a doctor.
The same tension between lifestyle management and medical intervention that shapes the WHO's new pediatric guidelines also shows up in how doctors are already treating older adolescents. GLP-1 prescribing among teenagers rose sharply from 2017 to 2025, according to new data, yet nine out of ten teens who met the clinical criteria for bariatric surgery still did not receive a GLP-1 prescription. That gap suggests prescribing has grown faster than access has evened out, leaving many eligible teens without a treatment option that is increasingly common for others in their position. It is a reminder that guidelines and prescribing patterns do not always move at the same pace.
The common thread across today's stories is whether the system around a drug, a label, or a guideline can be trusted to work in a patient's favor, and the honest answer is not yet entirely settled. A parent weighing options for a child, a shopper reading a food label, a teenager working with a doctor on a prescription, and a clinician following new guidelines all benefit from the same approach. Ask what evidence actually supports the choice in front of you, and do not assume a label or a guideline has settled the question on its own.
Originally published on GLP-1 Nation.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.